JP2004530699A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004530699A5 JP2004530699A5 JP2002591027A JP2002591027A JP2004530699A5 JP 2004530699 A5 JP2004530699 A5 JP 2004530699A5 JP 2002591027 A JP2002591027 A JP 2002591027A JP 2002591027 A JP2002591027 A JP 2002591027A JP 2004530699 A5 JP2004530699 A5 JP 2004530699A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- pharmaceutical composition
- groups
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 morpholinylcarbonyl Chemical group 0.000 claims 24
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 10
- 239000003207 proteasome inhibitor Substances 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 8
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 6
- 206010013774 Dry eye Diseases 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 150000001413 amino acids Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 2
- 125000003180 beta-lactone group Chemical group 0.000 claims 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 229910052798 chalcogen Inorganic materials 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 238000009736 wetting Methods 0.000 claims 2
- 125000006290 2-hydroxybenzyl group Chemical group [H]OC1=C(C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000006289 hydroxybenzyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29272201P | 2001-05-21 | 2001-05-21 | |
| PCT/US2002/015775 WO2002094311A1 (en) | 2001-05-21 | 2002-05-17 | Use of proteasome inhibitors to treat dry eye disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004530699A JP2004530699A (ja) | 2004-10-07 |
| JP2004530699A5 true JP2004530699A5 (OSRAM) | 2005-12-22 |
Family
ID=23125916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002591027A Pending JP2004530699A (ja) | 2001-05-21 | 2002-05-17 | ドライアイ障害を処置するためのプロテオソームインヒビターの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6740674B2 (OSRAM) |
| EP (1) | EP1392355B1 (OSRAM) |
| JP (1) | JP2004530699A (OSRAM) |
| CN (1) | CN1509183A (OSRAM) |
| AT (1) | ATE353667T1 (OSRAM) |
| AU (1) | AU2002308760B2 (OSRAM) |
| BR (1) | BR0209883A (OSRAM) |
| CA (1) | CA2447909C (OSRAM) |
| CY (1) | CY1107531T1 (OSRAM) |
| DE (1) | DE60218153T2 (OSRAM) |
| DK (1) | DK1392355T3 (OSRAM) |
| ES (1) | ES2278049T3 (OSRAM) |
| MX (1) | MXPA03010634A (OSRAM) |
| PL (1) | PL367287A1 (OSRAM) |
| PT (1) | PT1392355E (OSRAM) |
| WO (1) | WO2002094311A1 (OSRAM) |
| ZA (1) | ZA200308768B (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005099687A2 (en) | 2004-04-09 | 2005-10-27 | President And Fellows Of Harvard College | Analogs of salinosporamide a |
| WO2006062732A2 (en) * | 2004-11-19 | 2006-06-15 | Synta Pharmaceuticals Corp. | Compounds acting at the centrosome |
| US7465720B2 (en) | 2005-09-12 | 2008-12-16 | President And Fellows Of Harvard College | Proteasome inhibiting β-lactam compounds |
| ES2415756T3 (es) | 2005-11-09 | 2013-07-26 | Onyx Therapeutics, Inc. | Compuestos para la inhibición de enzimas |
| ES2415632T3 (es) | 2006-06-19 | 2013-07-26 | Onyx Therapeutics, Inc. | Epoxicetonas peptídicas para la inhibición del proteosoma |
| EP2207791B2 (en) | 2007-10-04 | 2019-08-07 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| EA024364B1 (ru) | 2008-10-21 | 2016-09-30 | Оникс Терапьютикс, Инк. | Способ лечения множественной миеломы |
| TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
| EP2542238B1 (en) | 2010-03-01 | 2015-08-12 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
| BR112012025264A2 (pt) | 2010-04-07 | 2019-09-24 | Onyx Therapeutics Inc | inibidor de imunoproteassoma de e´poxicetona peptídica cristalina. |
| US9126997B1 (en) | 2010-09-07 | 2015-09-08 | Northwestern University | Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma |
| UY34897A (es) | 2012-07-09 | 2014-01-31 | Onyx Therapeutics Inc | Profarmacos de inhibidores peptidicos de expoxi cetona proteasa |
| CN103893742B (zh) * | 2014-03-03 | 2016-01-20 | 中山大学中山眼科中心 | 含卵黄膜外层蛋白1在制备治疗干眼药物中的应用 |
| CN107151255A (zh) * | 2016-03-06 | 2017-09-12 | 复旦大学 | 硼酸类化合物及其制备方法和用途 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3991759A (en) | 1975-10-28 | 1976-11-16 | Alza Corporation | Method and therapeutic system for treating aqueous deficient dry eye |
| US4131651A (en) | 1977-10-25 | 1978-12-26 | Barnes-Hind Pharmaceuticals, Inc. | Treatment of dry eye |
| US4409205A (en) | 1979-03-05 | 1983-10-11 | Cooper Laboratories, Inc. | Ophthalmic solution |
| US4370325A (en) | 1979-03-30 | 1983-01-25 | Dermik Laboratories | Pharmaceutical compositions and method of treatment |
| US4744980A (en) | 1986-04-28 | 1988-05-17 | Holly Frank J | Ophthalmic solution for treatment of dry eye syndrome |
| US4883658A (en) | 1986-04-28 | 1989-11-28 | Holly Frank J | Ophthalmic solution for treatment of dry-eye syndrome |
| US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| US4818537A (en) | 1986-10-21 | 1989-04-04 | Liposome Technology, Inc. | Liposome composition for treating dry eye |
| US4966773A (en) | 1986-11-25 | 1990-10-30 | Alcon Laboratories, Inc. | Topical ophthalmic compositions containing microfine retinoid particles |
| US4914088A (en) | 1987-04-02 | 1990-04-03 | Thomas Glonek | Dry eye treatment solution and method |
| US5278151A (en) | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
| US5075104A (en) | 1989-03-31 | 1991-12-24 | Alcon Laboratories, Inc. | Ophthalmic carboxy vinyl polymer gel for dry eye syndrome |
| US5174988A (en) | 1989-07-27 | 1992-12-29 | Scientific Development & Research, Inc. | Phospholipid delivery system |
| US5583150A (en) | 1989-08-18 | 1996-12-10 | Alcon Laboratories, Inc. | 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases |
| US5041434A (en) | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| EP0459148B1 (en) | 1990-05-29 | 1996-01-03 | Ocular Research Of Boston Inc. | Dry eye treatment composition |
| ZA912797B (en) | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| ZA927277B (en) | 1991-10-02 | 1993-05-19 | Boston Ocular Res | Dry eye treatment process and solution. |
| US5958912A (en) | 1992-04-21 | 1999-09-28 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β |
| WO1993020823A1 (en) | 1992-04-21 | 1993-10-28 | The Schepens Eye Research Institute, Inc. | Ocular androgen therapy in sjögren's syndrome |
| US6107289A (en) | 1992-04-21 | 2000-08-22 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β |
| US5290572A (en) | 1992-08-06 | 1994-03-01 | Deo Corporation | Opthalmic composition for treating dry eye |
| US5474979A (en) | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
| US5696166A (en) | 1995-10-31 | 1997-12-09 | Yanni; John M. | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
| WO1997020578A1 (en) | 1995-12-04 | 1997-06-12 | University Of Miami | Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance |
| JPH1036289A (ja) | 1996-07-24 | 1998-02-10 | Sumitomo Pharmaceut Co Ltd | 神経細胞の変性または死滅抑制剤 |
| US6071904A (en) | 1996-12-11 | 2000-06-06 | Alcon Laboratories, Inc. | Process for manufacturing ophthalmic suspensions |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| CN1159061C (zh) | 1997-02-15 | 2004-07-28 | 千年药物公司 | 通过nf-kappab的抑制治疗梗塞 |
| EP1017398A1 (en) | 1997-09-25 | 2000-07-12 | Proscript, Inc. | Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases |
| CA2219867A1 (en) | 1997-10-31 | 1999-04-30 | Jiangping Wu | The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
| BR9906772A (pt) | 1998-07-14 | 2000-09-26 | Alcon Lab Inc | Uso de ácido 11-(3-dimetilamino-propilideno)-6,11diidrodibenz[b,e]o xepin-2-acético para a fabricação de um medicamento para tratamento de desordens inflamatórias oftálmicas não-alérgicas e para prevenção de neovascularização ocular |
| US6096733A (en) | 1998-12-10 | 2000-08-01 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| WO2000043000A1 (en) | 1999-01-20 | 2000-07-27 | Kyowa Hakko Kogyo Co., Ltd. | Proteasome inhibitors |
| US6254860B1 (en) | 1999-04-13 | 2001-07-03 | Allergan Sales, Inc. | Ocular treatment using cyclosporin-A derivatives |
| JP2002543058A (ja) | 1999-04-27 | 2002-12-17 | ノバルティス アクチエンゲゼルシャフト | プロテアソーム・インヒビターとしての２，４−ジアミノ−３−ヒドロキシカルボン酸誘導体の使用 |
-
2002
- 2002-05-17 BR BR0209883-0A patent/BR0209883A/pt not_active Application Discontinuation
- 2002-05-17 AU AU2002308760A patent/AU2002308760B2/en not_active Ceased
- 2002-05-17 CA CA2447909A patent/CA2447909C/en not_active Expired - Fee Related
- 2002-05-17 EP EP02771849A patent/EP1392355B1/en not_active Expired - Lifetime
- 2002-05-17 PT PT02771849T patent/PT1392355E/pt unknown
- 2002-05-17 MX MXPA03010634A patent/MXPA03010634A/es active IP Right Grant
- 2002-05-17 PL PL02367287A patent/PL367287A1/xx not_active Application Discontinuation
- 2002-05-17 WO PCT/US2002/015775 patent/WO2002094311A1/en not_active Ceased
- 2002-05-17 JP JP2002591027A patent/JP2004530699A/ja active Pending
- 2002-05-17 ES ES02771849T patent/ES2278049T3/es not_active Expired - Lifetime
- 2002-05-17 DE DE60218153T patent/DE60218153T2/de not_active Expired - Lifetime
- 2002-05-17 US US10/150,191 patent/US6740674B2/en not_active Expired - Lifetime
- 2002-05-17 DK DK02771849T patent/DK1392355T3/da active
- 2002-05-17 CN CNA028098544A patent/CN1509183A/zh active Pending
- 2002-05-17 AT AT02771849T patent/ATE353667T1/de active
-
2003
- 2003-11-11 ZA ZA2003/08768A patent/ZA200308768B/en unknown
-
2007
- 2007-03-13 CY CY20071100343T patent/CY1107531T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004530699A5 (OSRAM) | ||
| RU2395500C2 (ru) | 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств | |
| RU2219167C2 (ru) | N-замещенные аминотетралины как лиганды для рецептора y5 нейропептида y, полезные при лечении ожирения и других расстройств | |
| MY136034A (en) | New medicaments for the treatment of chronic obstructive pulmonary disease | |
| CY1107850T1 (el) | Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους | |
| EA201000643A1 (ru) | Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе | |
| SE0300010D0 (sv) | Novel Compounds | |
| WO2005056524A3 (en) | Therapeutic agents useful for treating pain | |
| TNSN04246A1 (fr) | Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation | |
| JP2002501049A5 (OSRAM) | ||
| SE0302760D0 (sv) | New compounds | |
| JP2006509749A5 (OSRAM) | ||
| JP2001526218A5 (OSRAM) | ||
| TNSN04165A1 (en) | Substituted hydroxyethylamines | |
| SE0301886D0 (sv) | New use V | |
| WO2004026863A8 (en) | Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors | |
| UA85708C2 (ru) | Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей | |
| PT1251846E (pt) | Taxanos com carbonato c-4 | |
| JP2003522198A5 (OSRAM) | ||
| RU2007119390A (ru) | Соединения 4-метоксиметил-пирролидин-2-карбоновой кислоты и их производные - ингибиторы вируса гепатита с | |
| RU2007131435A (ru) | Противоопухолевое средство | |
| HUP0402515A2 (hu) | Szubsztituált új N-[4-(1H-imidazol-1-il)-2-fluor-fenil]-3-(trifluor-metil)-1H-pirazol-5-karboxamidok Xa faktor inhibitorok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| JP2003509494A5 (OSRAM) | ||
| PT871626E (pt) | Triazolonas utilizadas como inibidores de sintese da apoliproteina b | |
| TW200640465A (en) | New pharmaceutically active compounds for the treatment of respiratory diseases |